<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00503711</url>
  </required_header>
  <id_info>
    <org_study_id>D4200L00004</org_study_id>
    <nct_id>NCT00503711</nct_id>
  </id_info>
  <brief_title>Phase I Chinese PK</brief_title>
  <official_title>An Open Label, Phase I, Rising Multiple Dose, Single Centre Study to Determine the PK and Tolerability of ZD6474 at Different Dose Levels in Chinese Patients With Solid Malignancy Tumor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      An open, phase 1 to assess the PK of rising doses of ZD6474 when administered daily in
      Chinese patients with advanced solid malignant tumors.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the curve (AUC) (0-24) (ng.h/mL) after single dose</measure>
    <time_frame>Blood sample is collected at 1, 2, 4, 6, 8, 10 &amp; 24 hour after first single dose on day 1</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Advanced Solid, Malignant Tumors</condition>
  <arm_group>
    <arm_group_label>100 mg Vandetanib eod</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mg Vandetanib every other day dosing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>100 mg Vandetanib od</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mg Vandetanib once daily dosing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>300 mg Vandetanib od</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 mg Vandetanib once daily dosing</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vandetanib</intervention_name>
    <description>100 mg every other day, 100mg once daily</description>
    <arm_group_label>100 mg Vandetanib eod</arm_group_label>
    <arm_group_label>100 mg Vandetanib od</arm_group_label>
    <other_name>ZD6474</other_name>
    <other_name>ZACTIMA™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vandetanib 300 mg</intervention_name>
    <description>300mg once daily</description>
    <arm_group_label>300 mg Vandetanib od</arm_group_label>
    <other_name>ZD6474</other_name>
    <other_name>ZACTIMA™</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histological and/or cytological confirmation of a malignant solid tumor

          -  refractory to standard therapies or for which no appropriate therapies exist

          -  WHO performance status 0-2

        Exclusion Criteria:

          -  patients with brain tumors or symptomatic cerebral metastases

          -  systemic anticancer therapy within the last 4 weeks
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Zhang L, Li S, Zhang Y, Zhan J, Zou BY, Smith R, Martin PD, Jiang Y, Liao H, Guan Z. Pharmacokinetics and tolerability of vandetanib in Chinese patients with solid, malignant tumors: an open-label, phase I, rising multiple-dose study. Clin Ther. 2011 Mar;33(3):315-27. doi: 10.1016/j.clinthera.2011.04.005.</citation>
    <PMID>21600385</PMID>
  </reference>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 18, 2007</study_first_submitted>
  <study_first_submitted_qc>July 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 19, 2007</study_first_posted>
  <last_update_submitted>August 29, 2016</last_update_submitted>
  <last_update_submitted_qc>August 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 31, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ZD6474 PK</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

